119results about "Cardiovascular disorder" patented technology

Described herein are methods of inhibiting M-CSF activity, and, in particular, M-CSF/c-fms dependent cell signaling. In a first embodiment of the invention, one administers to a mammal viral vectors that deliver genes experessing antisense c-fms RNA; in a second embodiment, one induces in vivo production of a high-affinity soluble c-fms protein that competes for non-bound M-CSF; in a third embodiment, one administers a ribozyme-viral vector against c-fms mRNA; and in a fourth embodiment, one administers oligodeoxynucleotides that inhibit expression of c-fms gene product. The methods may be used to treat any disease in which M-CSF activity plays a role, and are particularly effective in treating and preventing atherosclerosis.

Embodiments of the present invention are directed primarily, but not exclusively, to a method for treating and preventing cardiovascular disease by inhibiting receptors to M-CSF. Other embodiments of the present invention include any and all biologic and/or pathobiologic phenomena mediated in whole or in part by M-CSF signaling through its receptor. Pathobiologic phenomena include, but are not limited to, disease entities such as osteoporosis, Alzheimer's disease, diabetes mellitus (Type 1 and/or Type 2), infectious diseases, cancer, and inherited disorders characterized by defects in one or more components in the M-CSF signaling pathway.

A process is provided for preparing spiro-hydantoin compounds of the formula II

wherein Z is N or CR_4b; K and L are independently O or S; Ar is an optionally substituted aryl or heteroaryl; A₂ is a linker, G′ is a linker; Q is a linker; and R₂, R_4a, R_4c, and R_h are defined in the specification. The process optionally includes the enantiomeric separation of intermediates to allow preparation of enantiomers of the spiro-hydantoin compounds of formula II. Substituted spiro-hydantoin compounds may be prepared from the spiro-hydantoin compounds of formula II. The spiro-hydantoin compound of formula II and the substituted spiro-hydantoin compounds are useful in the treatment of immune or inflammatory diseases. Also, provided are products made by the instant inventive process and crystalline forms (prepared by any process) of the substituted spiro-hydantoin compound, 5-[(5S, 9R)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-ylmethyl]-thiophene-3-carboxylic acid, including solvates and salts thereof, as well as methods of use thereof. Crystalline forms of certain intermediates are provided.

The present invention provides methods, compositions, and kits for the treatment of disorders associated with overactivation of FGFR3, such as achondroplasia; bone or cartilage disorders; or vascular smooth muscle disorders, or for the elongation of bone. In some embodiments, the present invention provides polypeptides having a natriuretic peptide fused to an Fc domain of an immunoglobulin. Such polypeptides can be administered to subjects, e.g., subcutaneously, to treat a disorder associated with overactivation of FGFR3, a bone or cartilage disorder, or a vascular smooth muscle disorder, or to elongate bone. The invention also features nucleic acid molecules encoding such polypeptides and the use of the nucleic acid molecules for treating disorders associated with overactivation of FGFR3, bone or cartilage disorders, or vascular smooth muscle disorders, or for elongating bone.

The present invention relates to a method for processing human placental cell sample, a human placental cell sample obtained according to said method for processing human placental cell sample, a human placental cell bank, a method for banking human placental cells, a method for searching human placental cell sample in said human placental cell bank according to the present invention, a method for preparing human cord blood serum, use of human placental cells obtained by said method for processing human placental cell sample or human placental cell bank established by said method for banking human placental cells in treating human dysfunction and diseases due to cell injury or cell malfunction, as well as a method for treating human dysfunction and diseases due to cell injury or cell malfunction.

Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite.

Fibrin-binding peptides having high binding affinity and excellent physical characteristics compared to previously known fibrin-binding peptides are provided. These fibrin-binding peptides may be conjugated to a detectable label or a therapeutic agent and used to detect and facilitate treatment of pathological conditions associated with the presence of fibrin such as thrombic, angiogenic and neoplastic conditions. These peptides may be used in imaging processes such as MRI, ultrasound and nuclear medicine imaging (e.g. PET, scintigraphic imaging., etc.). The peptides may also be used therapeutically. The present invention also provides processes and methods for making and using such peptides and conjugates thereof.

A medication having nicotinamide mononucleotide as the active ingredient, and the use of nicotinamide mononucleotide in preparing medications for the prevention and treatment of arteriosclerosis and cardiovascular and cerebrovascular diseases caused by arteriosclerosis.

The present invention is to provide an imidazolidinedione derivative and oxazolidinedione derivative represented by the following general Formula (I) having the chymase and/or tryptase inhibition activity [wherein R<1 >and R<2 >are the same or different, and denote a lower alkyl group or a phenyl group, or R<1 >and R<2 >are taken together to form a ring, R<3 >denotes an optionally substituted naphthyl group or heterocyclic group, A denotes oxygen or NR<4 >(R<4 >is hydrogen or optionally substituted lower alkyl group), or NB<2>R<5 >(R<5 >is aryl group, and B<2 >is carbonyl group or sulfonyl group), and B<1 >denotes a carbonyl group or a sulfonyl group], or a pharmaceutically acceptable salt thereof.

Novel MCP-1 splice variant polypeptides and polynucleotides encoding same are provided. Also provided are pharmaceutical compositions comprising the splice variant polypeptides and polynucleotides, vectors and host cells comprising same. The compositions of the present invention are useful to treat various MCP-1 related disorders as well as for diagnosing, determining predisposition and/or prognosis of various disorders.

The invention provides a preparation method of an LCZ696 sustained release matrix tablet. The specific prescription of the LCZ696 sustained release tablet comprises (g/g): 40% of a main drug, 10%-20% of a matrix material, 30%-40% of a diluent, and 5%-10% of a lubricant. The preparation method consists of: sieving the raw and auxiliary materials by a 80-mesh sieve respectively for standby use, firstly mixing the main drug with the matrix material evenly, then adding the diluent and the lubricant and mixing the materials evenly, and performing all powder direct compression, thus obtaining the LCZ696 sustained release matrix tablet. The sustained release tablet is used for medication once every 24h, and the number of medication times is reduced. After oral taking, drugs are released slowly, the blood concentration is stable, and peak valley phenomenon is not generated. Also, the toxic and side effects of drugs are reduced.

The present invention relates to a method for preparing t-butyl 2-((4R,6S)-6-formyl-2,2-dimethyl-1,3-dioxan-4-yl)acetate having optical activity, which is a core intermediate in the preparation of a variety of HMG-CoA reductase inhibitors. According to the preparation method of the present invention, it is possible to easily mass-produce t-butyl 2-((4R,6S)-6-formyl-2,2-dimethyl-1,3-dioxan-4-yl)acetate in the form of a solid of high and uniform purity by using a polymer-supported TEMPO.

The invention discloses a suppository for treating haemorrhoids, and belongs to external traditional Chinese medicines for treating haemorrhoids. The suppository is prepared from golden cypress, scutellaria baicalensis, gallnuts and radix sophorae flavescentis by the following steps: 1) adding the golden cypress into ethanol 8 times by weight, carrying out reflux extraction three times, and concentrating the filtrate to obtain golden cypress concentrated liquor; 2) decocting the scutellaria baicalensis for 10 minutes by boiled water 14 times by weight of residual three medicinal materials, adding the gallnuts and the radix sophorae flavescentis and decocting for 2 hours, and filtering; 3) then, adding water 12 times by weight to decoct twice, combining the filtrates obtained by three times, and concentrating to obtain a fluid extract with relative density of 1.10-1.15; 4) adding ethanol into the fluid extract, standing for 18 hours, filtering and concentrating to obtain concentrated extracting liquor; 5) combining the concentrated extracting liquor and the golden cypress concentrated liquor, vacuum-drying and crushing to obtain medical powder; and 6) after uniformly mixing the medical powder with a matrix in a weight ratio of 4:6, carrying out injection moulding and cooling to obtain the suppository. The suppository disclosed by the invention has a good curative effect on hemorrhage, swelling, pains, constipation and the like caused by internal hemorrhoids, external hemorrhoids and mixed hemorrhoids, and is an external medicine for treating haemorrhoids.

The invention discloses a traditional Chinese medicine combination used for treating rheumatic heart disease and pertains to the Chinese medicine field. The Chinese medicine preparation takes the following ingredients as the active ingredients: root of rehmannia, radix codonopsis pilosulae, red sage root, fourstamen stephania root, medical glue, radices polygonati officinalis, lilyturf root, cassia twig, fructus schizandrae, liquorice and wu chia pee. The traditional Chinese medicine combination used for treating rheumatic heart disease have the effects of benefiting vital energy, enriching the blood, enheartening the heart-yang, nourishing the heart, benefiting the pulse, promoting blood circulation by removing blood stasis and repairing an impaired heart valve.

The invention relates to an active pure snake powder capsule and a preparation technique thereof. The invention adopts the technical scheme that the active pure snake powder capsule is prepared from Agkistrodon halys freeze-drying powder and black-tail snake freeze-drying powder according to the weight ratio of 2-3:1. The preparation technique comprises the following steps: delivering the washed Agkistrodon halys and the washed black-tail snake into a freezing dryer and freezing for 7-9 hours at negative 45 DEG C to negative 35 DEG C; starting a vacuum pump and heating to sublimate for 9-11 hours at 25-35 DEG C under a state of the vacuum degree of 1.3-13Pa; heating to sublimate for 11-13 hours at 55-65 DEG C; heating to sublimate for 9-11 hours at 75-85 DEG C; after vacuum drying, pulverizing the Agkistrodon halys and the black-tail snake coarsely by a roller respectively, then pulverizing finely and obtaining Agkistrodon halys freeze-drying powder and black-tail snake freeze-drying powder; and mixing the Agkistrodon halys freeze-drying powder and the black-tail snake freeze-drying powder evenly according to the weight ratio of 2-3:1, sieving with a sieve of 80 meshes and granulating a sieved substance by a capsule granulating machine after sterilizing by microwave. The invention can retain all the effective components of a snake, has curative effect to the three-high and is convenient to eat.

A dispersing tablet of Xindakang with high solubility and disintegrating speed for treating ischemic heart disease, arrhythmia, hypertension, hyperlipemia, hyperviscosity blood, etc is prepared from flavone acetylsalicylate and proper additive. Its preparing process is also disclosed.

The invention relates to a Chinese medicinal preparation for treating spermophlebectasia, wherein the reactive constituents are prepared from the following raw materials (by weight portion): ledebouriella root 6-12, dahurian angelica root 6-9, dried orange peel 8-10, red peony root 6-9, Chinese angelica root 9-12, pangolin scales 9-12, Chinese honey locust 9-12, myrrh 3-5, licorice root 4-6, honeysuckle flower 10-15, root of Chinese trichosannthes 10-15, bupleurum root 4-6, Sichuan fritillary bulb 9-12, frank incense 3-6, phellodendron bark 8-10, plantain seeds 8-10. The medicament can be prepared into dose forms of oral liquids, capsules, tablets, pills or powders.

The present invention provides transgenic mice deficient in corticotropin releasing factor receptor 2 (CRFR2). Mice deficient for CRFR1 exhibit decreased anxiety-like behavior and a decreased stress response. In contrast, CRFR2 null mutant mice are hypersensitive to stress and display increased anxiety-like behavior. These mice are useful for the study of anxiety, depression, and the physiology of the HPA axis. CRFR2 null mutant mice also exhibit increased angiogenesis in all tissues examined. Thus, CRFR2 antagonists may be used to stimulate angiogenesis for the treatment of various conditions. In contrast, CRFR2 agonists may be used to inhibit angiogenesis. A combination of urocortin and bFGF was observed to stimulate rapid hair growth.

The invention belongs to the technical field of food biology, and discloses a soybean peptide with high ACE inhibitory activity, and a preparation method and application of the soybean peptide. The soybean peptide has the high ACE inhibitory activity, and the preparation method comprises the following steps of adding alkaline protease to soybean protein isolate for enzymolysis to obtain an enzymolysis product; separating the enzymolysis product with a membrane ultrafiltration method to obtain soybean peptide powder I; further purifying the soybean peptide powder I with an ethanol fractionationmethod to obtain soybean peptide powder II; and further separating and purifying the soybean peptide powder II by using active carbon adsorption chromatography to obtain the soybean peptide with thehigh ACE inhibitory activity. The soybean peptide has the excellent ACE inhibitory activity and the good blood pressure reducing effect, can be applied to the field of food and health products, and the preparation method is simple and controllable and is suitable for mass production in factories.

The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula:

wherein one of Q and T represents a group represented by the general formula:

while the other represents a lower alkyl group or a halo(lower alkyl) group; R¹ represents a hydrogen atom, an optionally substituted lower alkyl group, a lower alkenyl group, a cyclic lower alkyl group, etc.; R² represents a hydrogen atom, an optionally substituted lower alkyl group, a lower alkoxy group, a lower alkenyl group, a cyclic lower alkyl group, a cyclic lower alkoxy group, etc., which exert an excellent inhibitory activity in human SGLT2, and therefore are useful as drugs for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, pharmaceutically acceptable salts thereof or prodrugs thereof, production intermediates thereof and pharmaceutical uses thereof.